Dendrobium candidum polysaccharide reduce atopic dermatitis symptoms and modulate gut microbiota in DNFB-induced AD-like mice

Yiheng Liang; Guangrong Liu; Lingna Xie; Kewen Su; Xia Chang; Yani Xu; Junsong Chen; Zhenyuan Zhu; Kaiye Yang; Huixiong Chen; Zhiyun Du

doi:10.3389/fphys.2022.976421

Dendrobium candidum polysaccharide reduce atopic dermatitis symptoms and modulate gut microbiota in DNFB-induced AD-like mice

Front Physiol. 2022 Sep 9:13:976421. doi: 10.3389/fphys.2022.976421. eCollection 2022.

Authors

Yiheng Liang^{1

2}, Guangrong Liu³, Lingna Xie^{1

2}, Kewen Su¹, Xia Chang¹, Yani Xu¹, Junsong Chen¹, Zhenyuan Zhu^{1

4}, Kaiye Yang³, Huixiong Chen^{1

5}, Zhiyun Du¹

Affiliations

¹ School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, China.
² Guangdong Provincial Key Laboratory of Plant Resources Biorefinery, Guangdong University of Technology, Guangzhou, China.
³ Research and Development Center, Infinitus (China) Co., Ltd., Guangzhou, China.
⁴ State Key Laboratory of Food Nutrition and Safety, College of Food Science and Engineering, Tianjin University of Science and Technology, Tianjin, China.
⁵ Chemistry of RNA, Nucleosides, Peptides and Heterocycles, CNRS UMR8601, Université Paris Descartes, PRES Sorbonne Paris Cité, UFR Biomédicale, Paris, France.

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease with a high prevalence worldwide. Increasing evidence suggests that the gut microbiota plays an important role in the pathogenesis of AD. In this study, we sought to verify the effect of Dendrobium candidum polysaccharides (DCP) on AD induced by 2,4-Dinitrofluorobenzene (DNFB) in Balb/c mice regarding its impact on the intestinal microbiome. We found that 2-week oral administration of DCP improved AD-like symptoms and histological damage of skin, reduced mast cell infiltration, down-regulated the level of serum total IgE and the expression of pro-inflammatory cytokines such as TNF-α, IFN-γ, IL-4 and IL-6, and increased the expression level of anti-inflammatory cytokine IL-10. The beneficial effect of DCP was attributed to the restoration of the intestinal microbiome composition and the unbalance of the intestinal homeostasis. Our results indicated that DCP might be used as a promising novel microbiota-modulating agent for the treatment of AD.

Keywords: atopic dermatitis; dinitrofluorobenzene; gut microbiota; inflammatory cytokine; plant polysaccharide.